cheynew, we are talking about a 'niche' market. There is money to make by players who know how to do this. But there aren't so many as the main stream BP's because many of them are specialized within certain fields.
So, they know that too! But in the end they need drugs to bring on the market. So PPHM can leave it there and wait because it cannot get more worthless then ZERO (if it would get worthless).
But crossing the brain-blood barrier is still a challenge and Cotara is a good approach to drop the drug directly inside the brain. And it can be use with other solid cancer in case targeting remains a problem. A light radio active element that makes huge damage inside the tumour, having the tumour itself protect/shield its environment, was/is a good approach compared to chemo that impacts healthy cells in the complete body and radio that is tremendously destructive on the path through the tumour.
So if immuno+bavi doesn't result in better targeting and if patients keep dying from the collateral cell damage because not even Bavi would be able to start up the immune system sufficiently fast and intensive to have repairs done, then this Cotara approach, or Cotara+Bavi both with almost no side effects, is a good one. Brain is the most difficult case because of the physical access.
Now, if in 5 years from know they didn't partner it then just throw it away. In that case there isn't any partner interested and that will then probably be because our other horse, Bavituximab, has drastically contributed to change the cancer landscape in combinations with immuno-oncology drug such as CTLA-4, PD-1, etc. IMO
Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.
